Wesley Smith, DO
Hematology & Oncology · Huntsville, ALNPI 1316472525
Payments from drug & device makers
Across 122 payments — averaging $43.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$2K
- AstraZeneca$354
- Boehringer Ingelheim$247
- Novartis$233
- E.r. Squibb & Sons, L.L.C.$233
- Lilly USA, LLC$214
- plus $2K from 30 others
What the payments were for
- Consulting fees$1,30024%
- Speaking & faculty fees$1202%
- Food & beverage$3,24361%
- Education$67813%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 13 | $1,677 |
| AstraZeneca(2 entities) | 13 | $354 |
| Boehringer Ingelheim | 5 | $247 |
| Novartis | 9 | $233 |
| E.r. Squibb & Sons, L.L.C. | 8 | $233 |
| Lilly USA, LLC | 2 | $214 |
| Daiichi Sankyo Inc. | 8 | $204 |
| Beigene USA, Inc. | 4 | $203 |
| Seagen Inc. | 2 | $200 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $182 |
| Gilead(2 entities) | 2 | $169 |
| Incyte Corporation | 3 | $138 |
| Medtronic | 1 | $131 |
| GSK | 2 | $129 |
| Johnson & Johnson | 2 | $116 |
| Beone Medicines USA, Inc. | 6 | $90 |
| Bristol Myers Squibb | 4 | $88 |
| Merck | 4 | $84 |
| Blueprint Medicines Corporation | 3 | $77 |
| Eisai Inc. | 3 | $71 |
| Agios Pharmaceuticals, Inc. | 2 | $50 |
| Stemline Therapeutics Inc. | 2 | $49 |
| Exelixis Inc. | 2 | $48 |
| Array Biopharma Inc | 3 | $46 |
| Servier Pharmaceuticals LLC | 3 | $43 |
| Sanofi | 2 | $39 |
| Bard Peripheral Vascular, Inc. | 1 | $37 |
| AVEO Pharmaceuticals, Inc. | 2 | $34 |
| Regeneron Healthcare Solutions, Inc. | 2 | $32 |
| Sobi, Inc | 1 | $24 |
| Jazz Pharmaceuticals Inc. | 1 | $22 |
| Deciphera Pharmaceuticals Inc. | 1 | $18 |
| Recordati_rare_diseases_inc. | 1 | $17 |
| Iovance Biotherapeutics, Inc. | 1 | $17 |
| Genmab U.S., Inc. | 1 | $16 |
| Edwards Lifesciences | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,342 in reported general payments places this provider in the 30th percentile of 177 hematology & oncology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Huntsville
- Lakshmikanth KatragaddaHuntsville$212K
- Daniel SchreederHuntsville$117K
- Jorge Diaz CastroHuntsville$75K
- Surrinder DangHuntsville$74K
- Brian MathewsHuntsville$71K
- Luciano CostaBirmingham$32.8M
- Amitkumar MehtaBirmingham$18.6M
- Erica Stringer-ReasorBirmingham$18.1M
- Susan BalBirmingham$11.3M
- Pankit VachhaniBirmingham$7.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.